This analysis revealed that neuroblastoma, rhabdomyosarcoma and kidney cancer cells were significantly sensitive to both LIMK inhibitors, with 6 additional cancer types being sensitive to either inhibitor and trending towards sensitivity to the other (e.g. Ewing's sarcoma, osteosarcoma and additional soft tissue cancer cell lines). Here, LIMK1 is linked to neuroblastoma.